Literature DB >> 18475591

Acute phase protein response and polymorphonuclear leukocyte cathepsin g release after slow interleukin-1 stimulation in the rat.

P Björk1, T Gudmundsson, K Ohlsson.   

Abstract

In this work we have studied the acute phase protein response and degranulation of polymorphonuclear leukocytes in vivo in the rat after a slow interleukin-1beta stimulation. A total dose of 1 mug, 2 mug, 4 mug and 0 mug (controls with only vehicle) of interleukin-1beta was released from osmotic minipumps over a period of 7 days. The pumps were implanted subcutaneously. A cystic formation was formed around the pumps that contained interleukin-1beta whereas no tissue reaction was seen around pumps containing only vehicle. Besides flbroblasts the cyst wall contained numerous polymorphonuclear leukocytes which were positively stained for cathespin G. alpha(2)-macroglobulin, alpha(1)-inhtbitor-3, alpha(1)-proteinase inhibitor, albumin and C3 were measured by electroimmunoassay and all showed plasma concentration patterns that were dose-dependent to the amount of interleuktn-1beta released. Fibrinogen in plasma was elevated in the control group but showed decreased plasma values with higher doses of interleukin-1beta released. All animals showed increased plasma levels of cathespin G but the lowest levels for cathespin G were seen for the highest interleukin-1beta dose released. It was clearly seen that a slow continuous release of interleukin-1beta in vivo caused an inflammatory reaction. Plasma levels for the proteins analysed all showed a similar pattern, namely an initial increase or decrease of plasma concentration followed by a tendency to normalization of plasma values. It was concluded that a long-term interleukin-1beta release could not sustain the acute phase protein response elicited by the initial interleukin-1beta release.

Entities:  

Year:  1994        PMID: 18475591      PMCID: PMC2365584          DOI: 10.1155/S0962935194000608

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  22 in total

1.  Cathepsin-G and leukocyte elastase inactivate human tumor necrosis factor and lymphotoxin.

Authors:  P Scuderi; P A Nez; M L Duerr; B J Wong; C M Valdez
Journal:  Cell Immunol       Date:  1991-07       Impact factor: 4.868

2.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor.

Authors:  C H Hannum; C J Wilcox; W P Arend; F G Joslin; D J Dripps; P L Heimdal; L G Armes; A Sommer; S P Eisenberg; R C Thompson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

3.  Interleukin-1 beta stimulates fibroblast elastase activity.

Authors:  F Croute; E Delaporte; J Y Bonnefoy; C Fertin; J Thivolet; J F Nicolas
Journal:  Br J Dermatol       Date:  1991-06       Impact factor: 9.302

4.  Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells.

Authors:  C Zoja; J M Wang; S Bettoni; M Sironi; D Renzi; F Chiaffarino; H E Abboud; J Van Damme; A Mantovani; G Remuzzi
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

5.  Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein.

Authors:  D B Carter; M R Deibel; C J Dunn; C S Tomich; A L Laborde; J L Slightom; A E Berger; M J Bienkowski; F F Sun; R N McEwan
Journal:  Nature       Date:  1990-04-12       Impact factor: 49.962

6.  Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist.

Authors:  S P Eisenberg; R J Evans; W P Arend; E Verderber; M T Brewer; C H Hannum; R C Thompson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

7.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock.

Authors:  K Ohlsson; P Björk; M Bergenfeldt; R Hageman; R C Thompson
Journal:  Nature       Date:  1990-12-06       Impact factor: 49.962

8.  Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55.

Authors:  H Tilg; E Trehu; M B Atkins; C A Dinarello; J W Mier
Journal:  Blood       Date:  1994-01-01       Impact factor: 22.113

9.  Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor.

Authors:  E V Granowitz; B D Clark; J Mancilla; C A Dinarello
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

10.  In vivo changes in plasma acute phase protein levels in the rat induced by slow release of IL-1, IL-6 and TNF.

Authors:  E J Lewis; A D Sedgwick; T H Hanahoe
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

View more
  1 in total

1.  alpha(2)-macroglobulin and alpha(1)-inhibitor-3 mRNA expression in the rat liver after slow interleukin-1 stimulation.

Authors:  T Gudmundsson; P Björk; K Ohlsson
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.